文献速递免疫规划

大流行性流感疫苗免疫原性评估要点:甲型H1N1pdm09流感疫苗免疫原性研究的启示

Key points in evaluating immunogenicity of pandemic influenza vaccines: A lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine.
PubMed 文献 · Vaccine · 2017-08-04

该综述通过检索PubMed和医中誌Web,纳入16篇关于甲型H1N1pdm09流感疫苗免疫原性的观察性研究,发现市售疫苗在所有研究人群中均满足国际免疫原性标准,免疫应答在初中生中最强、在血液系统恶性肿瘤患者中最弱,并讨论了患者背景、研究操作及既往季节性流感疫苗接种等因素对免疫原性评估的影响。

要点

  • 市售甲型H1N1pdm09流感疫苗在所有研究人群中均满足国际免疫原性标准。
  • 免疫应答在初中生中最强,在血液系统恶性肿瘤患者中最弱。
  • 患者背景、研究操作及既往季节性流感疫苗接种可能影响免疫原性评估。

核心结论

  • 本综述讨论了大流行性流感疫苗免疫原性评估中必须考虑和解决的因素与策略,可能为未来流感大流行提供有用信息。

研究设计与样本

  • 使用PubMed和医中誌Web检索观察性研究,检索词包括「influenza vaccine AND (immunogenicity OR immune response) AND Japan AND (2009 OR pdm09) NOT review」,限于人类研究。
  • 共鉴定33篇文章,其中16篇符合纳入标准。

主要发现

  • 市售甲型H1N1pdm09流感疫苗在所有研究人群中均满足流感疫苗免疫原性的国际标准。
  • 最显著的免疫应答见于初中生,最低的免疫应答见于血液系统恶性肿瘤患者。
  • 与季节性流感疫苗免疫原性研究类似,患者背景(如年龄、基础疾病、接种前滴度、体重指数等)和研究操作(如同时测量接种前后抗体滴度、研究期间感染的影响)可能影响甲型H1N1pdm09流感疫苗免疫原性评估。
  • 既往接种季节性流感疫苗可能抑制甲型H1N1pdm09流感疫苗诱导抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immunogenicity studies on pandemic influenza vaccine are necessary to inform rapid development and implementation of a vaccine during a pandemic. Thus, strategies for immunogenicity assessment are required. OBJECTIVE: To identify essential factors to consider when evaluating the immunogenicity of pandemic influenza vaccines using the experience in Japan with the influenza A(H1N1)pdm09 vaccine. METHODS: We conducted a search of observational studies using PubMed and IchushiWeb. Search terms included "influenza vaccine AND (immunogenicity OR immune response) AND Japan AND (2009 OR pdm09) NOT review," and was limited to studies conducted in humans. RESULTS: A total of 33 articles were identified, of which 16 articles met the inclusion criteria. Immunogenicity of the commercially available influenza A(H1N1)pdm09 vaccine satisfied the international criteria for influenza vaccine immunogenicity in all study populations. The most remarkable immune response was observed in junior high school students, while the lowest immune response was observed in hematological malignancy patients. Similar to immunogenicity studies on seasonal influenza vaccines, factors such as patient background (e.g., age, underlying condition, pre-vaccination titer, body mass index, etc.) and study procedure (e.g., concurrent measurement of pre- and post-vaccination antibody titer, effects of infection during the study period) may have affected the assessment of immunogenicity to the influenza A(H1N1)pdm09 vaccine. In addition, prior vaccination with the seasonal influenza vaccine may inhibit antibody induction by the influenza A(H1N1)pdm09 vaccine. CONCLUSIONS: This review discusses factors and strategies that must be considered and addressed during immunogenicity assessments of pandemic influenza vaccines, which may provide useful information for future influenza pandemics.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ohfuji S, Kobayashi M, Ide Y, et al. Key points in evaluating immunogenicity of pandemic influenza vaccines: A lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine. Vaccine. 2017. PMID: 28784284. doi:10.1016/j.vaccine.2017.07.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。